Last updated: 2026-09-09 10:37:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
X4 Pharmaceuticals, Inc. (XFOR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3,47, with a market capitalisation of $400,55M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,80 to $4,83. This page covers its latest market performance, valuation, price trends and company information.
$400,55M | |
$3,49 | |
$717,90 | |
$1,35 | |
$3,51 | |
267,00 | |
791,48K | |
-- | |
$4,83 | |
$2,80 | |
-- | |
-- |
X4 Pharmaceuticals, Inc. (XFOR) is trading at $3,47 in pre-market trading as of 2026-09-09 09:43:00, down 0,97% ($0,03) from the previous close of $3,51
Pre-market trading shows how investors are pricing XFOR before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, X4 Pharmaceuticals, Inc. (XFOR) moved from $4,04 to $3,47, representing a decline of 14,08% ($0,57).
The stock traded between $3,19 and $4,23 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 581,23 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33,1%
XFOR is currently trading at $3,47, placing it 33,1% of the way from its 52-week low of $2,80 to its 52-week high of $4,83. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 45 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of X4 Pharmaceuticals, Inc. (XFOR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.